Physician profile
Mark Lawrence Prochaska
NPI 1417953290
$855.15
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $74.75 · 2021: $252 · 2022: $209.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $315.66 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $217.66 | 2019 | |
| Lundbeck LLC | $133.00 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $84.62 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.88 | 2021 | |
| Vanda Pharmaceuticals INC. | $30.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$125.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Prochaska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.